Report Detail

CHAPTER 1. INTRODUCTION

  • 1.1. RESEARCH METHODOLOGY
    • 1.1.1. ERC DESK RESEARCH
    • 1.1.2. ERC DATA SYNTHESIS
    • 1.1.3. DATA VALIDATION AND MARKET FEEDBACK
    • 1.1.4. ERC DATA SOURCES

CHAPTER 2. ERYTHROPOIETIN DRUGS MARKET OVERVIEW

  • 2.1. ERYTHROPOIETIN DRUGS MARKET INTRODUCTION
  • 2.2. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    • 2.2.1. GLOBAL ERYTHROPOIETIN DRUGS PRODUCTION (VOLUME) AND GROWTH RATE (%), (2017-2025)
  • 2.3. GLOBAL ERYTHROPOIETIN DRUGS MARKET CAPACITY AND GROWTH RATE, 2017-2025
    • 2.3.1. GLOBAL ERYTHROPOIETIN DRUGS CAPACITY (VOLUME) AND GROWTH RATE (%), (2017-2025)
  • 2.4. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025
    • 2.4.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND GROWTH RATE (%), (2017-2025)
  • 2.5. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    • 2.5.1. GLOBAL ERYTHROPOIETIN DRUGS CONSUMPTION (VOLUME) AND GROWTH RATE (%), (2017-2025)

CHAPTER 3. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY DRUG CLASS, 2017-2025

  • 3.1. EPOETIN-ALFA
  • 3.2. EPOETIN-BETA
  • 3.3. DARBEPOETIN-ALFA
  • 3.4. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE BY DRUG CLASS, 2017-2025
    • 3.4.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY DRUG CLASS, 2017-2025
    • 3.4.2. EPOETIN-ALFA MARKET REVENUE AND GROWTH RATE, 2017-2025
    • 3.4.3. EPOETIN-BETA MARKET REVENUE AND GROWTH RATE, 2017-2025
    • 3.4.4. DARBEPOETIN-ALFA MARKET REVENUE AND GROWTH RATE, 2017-2025
  • 3.5. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION BY DRUG CLASS, 2017-2025
    • 3.5.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY DRUG CLASS, 2017-2025
    • 3.5.2. EPOETIN-ALFA MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    • 3.5.3. EPOETIN-BETA MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    • 3.5.4. DARBEPOETIN-ALFA MARKET PRODUCTION AND GROWTH RATE, 2017-2025

CHAPTER 4. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY APPLICATION, 2017-2025

  • 4.1. CANCER
  • 4.2. RENAL DISEASE
  • 4.3. HEMATOLOGY
  • 4.4. NEUROLOGY
  • 4.5. OTHERS
  • 4.6. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE BY APPLICATION, 2017-2025
    • 4.6.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY APPLICATION, 2017-2025
    • 4.6.2. CANCER MARKET REVENUE AND GROWTH RATE, 2017-2025
    • 4.6.3. RENAL DISEASE MARKET REVENUE AND GROWTH RATE, 2017-2025
    • 4.6.4. HEMATOLOGY MARKET REVENUE AND GROWTH RATE, 2017-2025
  • 4.7. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION BY APPLICATION, 2017-2025
    • 4.7.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY APPLICATION, 2017-2025
    • 4.7.2. CANCER MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    • 4.7.3. RENAL DISEASE MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    • 4.7.4. HEMATOLOGY MARKET CONSUMPTION AND GROWTH RATE, 2017-2025

CHAPTER 5. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY DRUG TYPE, 2017-2025

  • 5.1. BIOLOGICS
  • 5.2. BIOSIMILAR

CHAPTER 6. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY DISTRIBUTION CHANNEL, 2017-2025

  • 6.1. HOSPITAL PHARMACY
  • 6.2. RETAIL PHARMACY
  • 6.3. ONLINE PHARMACY

CHAPTER 7. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY REGION, 2017-2025

  • 7.1. NORTH AMERICA
    • 7.1.1. U.S.
    • 7.1.2. CANADA
    • 7.1.3. MEXICO
  • 7.2. EUROPE
    • 7.2.1. U.K.
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. ITALY
    • 7.2.5. SPAIN
    • 7.2.6. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. JAPAN
    • 7.3.3. INDIA
    • 7.3.4. KOREA
    • 7.3.5. REST OF APAC
  • 7.4. SOUTH AMERICA
    • 7.4.1. BRAZIL
    • 7.4.2. REST OF SOUTH AMERICA
  • 7.5. REST OF THE WORLD
    • 7.5.1. MIDDLE EAST
    • 7.5.2. AFRICA
  • 7.6. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE BY REGION, 2017-2025
    • 7.6.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY REGION, 2017-2025
    • 7.6.2. NORTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
    • 7.6.3. EUROPE MARKET REVENUE AND GROWTH RATE, 2017-2025
    • 7.6.4. ASIA PACIFIC MARKET REVENUE AND GROWTH RATE, 2017-2025
    • 7.6.5. SOUTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
    • 7.6.6. REST OF THE WORLD MARKET REVENUE AND GROWTH RATE, 2017-2025

CHAPTER 8. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025

  • 8.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
    • 8.1.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
    • 8.1.2. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
    • 8.1.3. NORTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
    • 8.1.4. EUROPE MARKET PRODUCTION AND CONSUMPTION, 2017-2025
    • 8.1.5. ASIA PACIFIC MARKET PRODUCTION AND CONSUMPTION, 2017-2025
    • 8.1.6. SOUTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
    • 8.1.7. REST OF THE WORLD MARKET PRODUCTION AND CONSUMPTION, 2017-2025

CHAPTER 9. MARKET DETERMINANTS

  • 9.1. MARKET DRIVERS
  • 9.2. MARKET RESTRAINTS
  • 9.3. MARKET OPPORTUNITIES
  • 9.4. MARKET DETERMINANTS RADAR CHART

CHAPTER 10. GLOBAL ERYTHROPOIETIN DRUGS MARKET COMPETITION BY MANUFACTURERS

  • 10.1. GLOBAL ERYTHROPOIETIN DRUGS PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
    • 10.1.1. GLOBAL ERYTHROPOIETIN DRUGS PRODUCTION (VOLUME) AND SHARE (%) BY MANUFACTURERS (2017-2025)
  • 10.2. GLOBAL ERYTHROPOIETIN DRUGS REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
    • 10.2.1. GLOBAL ERYTHROPOIETIN DRUGS REVENUE (MILLION USD) AND SHARE (%) BY MANUFACTURERS (2017-2025)
  • 10.3. ERYTHROPOIETIN DRUGS MARKET COMPETITIVE SITUATION AND TRENDS
    • 10.3.1. ERYTHROPOIETIN DRUGS MARKET SHARE (%) OF TOP 3 MANUFACTURERS
    • 10.3.2. ERYTHROPOIETIN DRUGS MARKET SHARE (%) OF TOP 5 MANUFACTURERS

CHAPTER 11. GLOBAL ERYTHROPOIETIN DRUGS MANUFACTURERS ANALYSIS

  • 11.1. LG LIFE SCIENCES LIMITED
    • 11.1.1. BUSINESS OVERVIEW
    • 11.1.2. COMPANY BASIC INFORMATION
    • 11.1.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.1.4. LG LIFE SCIENCES LIMITED ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
  • 11.2. RANBAXY LABORATORIES LTD
    • 11.2.1. BUSINESS OVERVIEW
    • 11.2.2. COMPANY BASIC INFORMATION
    • 11.2.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.2.4. RANBAXY LABORATORIES LTD ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
  • 11.3. TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 11.3.1. BUSINESS OVERVIEW
    • 11.3.2. COMPANY BASIC INFORMATION
    • 11.3.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.3.4. TEVA PHARMACEUTICAL INDUSTRIES LTD ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
  • 11.4. BIOCON LIMITED
    • 11.4.1. BUSINESS OVERVIEW
    • 11.4.2. COMPANY BASIC INFORMATION
    • 11.4.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.4.4. BIOCON LIMITED ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
  • 11.5. HOFFMANN-LA ROCHE AG
    • 11.5.1. BUSINESS OVERVIEW
    • 11.5.2. COMPANY BASIC INFORMATION
    • 11.5.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.5.4. HOFFMANN-LA ROCHE AG ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
  • 11.6. HOSPIRA INC.
    • 11.6.1. BUSINESS OVERVIEW
    • 11.6.2. COMPANY BASIC INFORMATION
    • 11.6.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.6.4. HOSPIRA INC. ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
  • 11.7. PFIZER INC.
    • 11.7.1. BUSINESS OVERVIEW
    • 11.7.2. COMPANY BASIC INFORMATION
    • 11.7.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.7.4. PFIZER INC. ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
  • 11.8. JOHNSON & JOHNSON LLC
    • 11.8.1. BUSINESS OVERVIEW
    • 11.8.2. COMPANY BASIC INFORMATION
    • 11.8.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.8.4. JOHNSON & JOHNSON LLC ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
  • 11.9. NOVARTIS INTERNATIONAL AG
    • 11.9.1. BUSINESS OVERVIEW
    • 11.9.2. COMPANY BASIC INFORMATION
    • 11.9.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.9.4. NOVARTIS INTERNATIONAL AG ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
  • 11.10. GLAXOSMITHKLINE PLC
    • 11.10.1. BUSINESS OVERVIEW
    • 11.10.2. COMPANY BASIC INFORMATION
    • 11.10.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    • 11.10.4. GLAXOSMITHKLINE PLC ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN

CHAPTER 12. ERYTHROPOIETIN DRUGS MARKET VALUE CHAIN ANALYSIS

  • 12.1. ERYTHROPOIETIN DRUGS INDUSTRIAL CHAIN ANALYSIS
  • 12.2. ERYTHROPOIETIN DRUGS KEY RAW MATERIALS ANALYSIS
    • 12.2.1. KEY RAW MATERIALS
    • 12.2.2. PRICE TREND OF KEY RAW MATERIALS
    • 12.2.3. KEY SUPPLIERS OF RAW MATERIALS
  • 12.3. CONSUMER ANALYSIS
    • 12.3.1. CONSUMER 1
    • 12.3.2. CONSUMER 2
    • 12.3.3. CONSUMER 3

“Erythropoietin Drugs Market” 2018-2026 report is a professional study on the current state of the market that focuses on the major drivers, challenges, opportunities for the leading players. The research report also offers a granular analysis of various definitions, and classification of the industry, applications of the industry, regional breakdown, opportunities, challenges, and chain structure.

About Erythropoietin Drugs Market

Erythropoietin Drugs Market is expected to grow with a CAGR of 7% during the forecast period of 2018 to 2025. Erythropoietin (EPO), also known as hematopoietin, is a glycoprotein hormone produced by kidneys, responsible for stimulating the bone marrow to produce red blood cells within the body. Erythropoietin drugs market is witnessing an impressive growth with the increasing prevalence of anemia among women, especially in the developing and under developed countries such as India, Nigeria and many others. Additionally, reimbursement policies for patients is yet another factor responsible for the growth of erythropoietin drugs market. However, side effects of erythropoietin drugs is creating hesitation among the patients to adopt these drugs, thus, hampering the growth of the erythropoietin drugs market. On the other hand, favorable government initiatives in order to promote the usage of generic drugs can put forward a lucrative growth platform for the drug manufacturers involved in generic drugs.

Market Summary:

The Erythropoietin Drugs market is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Erythropoietin Drugs Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

The study on the worldwide Erythropoietin Drugs market strives to offer substantial and profound insights into the current market scenario and the developing growth dynamics. Moreover, the report also provides the market players along with the new contenders a complete view of the market landscape. The inclusive research will enable the well-established as well as the entry-level players to establish their business strategies and accomplish their short-term and long-term goals.

Scope and Segmentation of the Report

The segment analysis is one of the significant sections of this report. Our expert analyst has categorized the market into product type, application/end-user, and geography. All the segments are analyzed based on their market share, growth rate, and growth potential. In the geographical classification, the report highlights the regional markets having high growth potential. This thorough evaluation of the segments would help the players to focus on revenue-generating areas of the Erythropoietin Drugs market.

Based on Type

Biologics
Biosimilar

Based on Application

Cancer
Renal Disease
Hematology
Neurology
Others

Regional Analysis

Our analysts are experts in covering all types of geographical markets from developing to mature ones. You can expect a comprehensive research analysis of key regional and country-level markets such as Europe, North America, South America, Asia-Pacific, and the Middle East & Africa. With accurate statistical patterns and regional classification, our domain experts provide you one of the most detailed and easily understandable regional analyses of the Erythropoietin Drugs market.

Competitive Landscape:

The research report also studied the key players operating in the Erythropoietin Drugs market. It has evaluated and explained the research & development stages of these companies, their financial performances, and their expansion plans for the coming years. Moreover, the research report also includes the list of planned initiatives that clearly explain the accomplishments of the companies in the recent past.

Company Coverage (Sales Revenue, Price, Gross Margin, Main Products, etc.):

LG Life Sciences Limited
Ranbaxy Laboratories Ltd
Teva Pharmaceutical Industries Ltd
Biocon Limited
Hoffmann-La Roche AG
Hospira Inc.
Pfizer Inc.
Johnson & Johnson LLC
Novartis International AG.
Amgen Inc
GlaxoSmithKline plc
Merck & Co
Wockhardt Ltd.

Research Methodology

The research methodology of the market is based on both primary as well as secondary research data sources. It compels different factors affecting the Erythropoietin Drugs industry such as historical data and market trends, different policies of the government, market environment, market risk factors, market restraints, technological advancements, forthcoming innovations, and obstacles in the industry.

The content of the study subjects includes a total of 8 chapters:

Chapter 1, describe the Erythropoietin Drugs market report’s – executive summary, market definition, and market scope. Moreover, the report helps in picking up the crucial information about the said market.

Chapter 2, defines the Research Methodology including primary research, assumptions & exclusions, and secondary data sources. The report follows the simultaneous top-down and bottom approach to provide you the accurate market sizing.

Chapter 3, explains the report segmentation & scope, key market trends (drivers, restraints, and opportunities), along with Porter’s five forces analysis and market share analysis

Chapter 4: It helps in understanding the key product segments and their future of the Erythropoietin Drugs Market. It provides strategic recommendations in key business segments based on the market estimations.

Chapters 5, and 6 to segment the sales by type and application/end-user, with sales market share and growth rate by type, application/end-user, from 2018 to 2016. Our team of Analysts and experts dedicatedly put their effort to provide you the best possible and accurate segmentation data and analysis.

Chapter 7, describes the regional segmentation based on the country level for the forecast period 2018 – 2026. The research report not only provide the market data of the five geographies but also provide the qualitative as well we qualitative information on country level bifurcation.

Chapter 8, to profile the top manufacturers of Erythropoietin Drugs, with price, sales, revenue and market share of Erythropoietin Drugs in 2016, 2017, and 2018. Players are expected to sign acquisition and collaboration deals to expand their products and services portfolio. Such strategic agreements could help them to improve their client base in other countries and gain a competitive advantage


Summary:
Get latest Market Research Reports on Erythropoietin Drugs . Industry analysis & Market Report on Erythropoietin Drugs is a syndicated market report, published as Erythropoietin Drugs Market By Drug Class (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa), By Drug Type (Biologics, Biosimilar), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Cancer, Renal Disease, Hematology, Neurology), Industry Trends, Estimation & Forecast, 2018 - 2025. It is complete Research Study and Industry Analysis of Erythropoietin Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$4,700.00
$5,600.00
3,427.73
4,084.11
3,949.00
4,705.19
515,566.50
614,292.00
351,424.64
418,718.72
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report